CCNY Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with disrupted CCNY, providing a loss-of-function model for cyclin Y. This mixed NCI-H1299 non-small cell lung carcinoma population with heterogeneous gene disruptions enables robust functional assessment without clonal artifacts. The CRISPR/Cas9-mediated gene depletion reduces endogenous CCNY protein, making the cells suitable for Wnt signal transduction and cell cycle assays. Researchers can dissect CCNY??s role in lung cancer biology free from single-cell clone limitations.
NCI-H1299 is a widely studied human non-small cell lung carcinoma model derived from a lymph node metastasis of lung adenocarcinoma. These epithelial cells exhibit a metastatic phenotype and serve to investigate NSCLC progression, invasion, and drug resistance. Lacking functional p53, NCI-H1299 cells provide a relevant genetic background for oncogenic Wnt/??-catenin signaling studies. Their extensive characterization makes them an ideal host for gene editing to elucidate factors like CCNY in lung cancer.
Cyclin Y (CCNY) binds and activates CDK14 (PFTK1), which phosphorylates the Wnt co-receptor LRP6 at critical residues. This phosphorylation enhances Wnt signaling downstream of WNT ligands, Frizzled receptors, and Dishevelled (DVL), promoting ??-catenin stabilization and nuclear translocation. Nuclear ??-catenin partners with TCF/LEF transcription factors to activate genes driving cell cycle progression and proliferation. CCNY thus links external Wnt inputs to intracellular transcriptional responses, with interactions involving CDK16 and other partners bolstering mitogenic signaling.
CCNY disruption in NCI-H1299 creates a powerful system to dissect Wnt/??-catenin contributions to metastatic lung adenocarcinoma. Aberrant Wnt activation is common in NSCLC tumorigenesis and therapy resistance; thus, this knockout model enables direct assessment of CCNY-dependent oncogenic processes like anchorage-independent growth, colony formation, and cell migration. Comparing polyclonal knockout to wild-type populations evaluates CCNY loss effects on cell cycle distribution and apoptosis in a p53-deficient background, relevant for studying synthetic lethal interactions or resistance mechanisms in such tumors.
Key applications include western blotting for CCNY and phospho-LRP6, RT-qPCR of Wnt targets like AXIN2 and MYC, and TOP/FOP flash reporter assays for ??-catenin/TCF transcription. Cell proliferation and colony formation assays functionally assess CCNY loss on growth. These polyclonal cells also support drug target validation, such as testing CDK14 inhibitors or synergy with standard agents. The CCNY Knockout NCI-H1299 Polyclonal Cells serve as a versatile tool for cancer biology and signal transduction research. For further details, contact Ascent Research.
